Stock News

Piper Jaffray Starts Ultragenyx (RARE) Coverage with $67.0 Target; Carlson Capital LP Has Boosted Its Pepsico (PEP) Position

Among 21 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 14 have Buy rating, 1 Sell and 6 Hold. Therefore 67% are positive. Ultragenyx Pharmaceutical Inc has $126 highest and $55.0 lowest target. $74.84’s average target is 43.02% above currents $52.33 stock price. Ultragenyx Pharmaceutical Inc had 61 analyst reports since July 27, 2015 according to SRatingsIntel. On Tuesday, December 5 the stock rating was maintained by Canaccord Genuity with “Buy”. H.C. Wainwright downgraded Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) rating on Wednesday, April 19. H.C. Wainwright has “Neutral” rating and $72 target. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Hold” rating by Barclays Capital on Wednesday, September 6. H.C. Wainwright initiated Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) on Tuesday, February 9 with “Buy” rating. JMP Securities maintained the shares of RARE in report on Wednesday, June 8 with “Market Outperform” rating. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Outperform” rating by Raymond James on Tuesday, September 1. Cowen & Co maintained Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) on Tuesday, August 22 with “Buy” rating. The firm has “Buy” rating by Robert W. Baird given on Tuesday, August 22. As per Monday, November 14, the company rating was downgraded by Citigroup. The firm earned “Buy” rating on Wednesday, February 21 by Stifel Nicolaus.

Carlson Capital LP increased Pepsico Inc (PEP) stake by 26.07% reported in 2017Q3 SEC filing. Carlson Capital LP acquired 33,533 shares as Pepsico Inc (PEP)’s stock rose 5.12%. The Carlson Capital LP holds 162,158 shares with $18.07 million value, up from 128,625 last quarter. Pepsico Inc now has $154.40B valuation. The stock decreased 1.06% or $1.16 during the last trading session, reaching $108.74. About 3.87 million shares traded. PepsiCo, Inc. (NYSE:PEP) has risen 12.20% since March 22, 2017 and is uptrending. It has underperformed by 4.50% the S&P500.

Since October 10, 2017, it had 0 insider buys, and 1 sale for $2.37 million activity. On Tuesday, October 10 Laguarta Ramon sold $2.37M worth of PepsiCo, Inc. (NASDAQ:PEP) or 21,449 shares.

Carlson Capital LP decreased Consolidated Tomoka Ld Co (NYSEMKT:CTO) stake by 8,888 shares to 171,000 valued at $10.27M in 2017Q3. It also reduced Level 3 Communications Inc (NYSE:LVLT) stake by 2.45M shares and now owns 969,000 shares. Onemain Hldgs Inc was reduced too.

Among 22 analysts covering PepsiCo (NYSE:PEP), 8 have Buy rating, 0 Sell and 14 Hold. Therefore 36% are positive. PepsiCo had 67 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, April 28 by BMO Capital Markets. The firm has “Hold” rating by Stifel Nicolaus given on Thursday, October 12. On Tuesday, March 21 the stock rating was initiated by JP Morgan with “Overweight”. The rating was maintained by RBC Capital Markets with “Hold” on Tuesday, September 5. RBC Capital Markets maintained it with “Sector Perform” rating and $102 target in Wednesday, October 7 report. On Thursday, October 5 the stock rating was maintained by RBC Capital Markets with “Sector Perform”. JP Morgan maintained the shares of PEP in report on Wednesday, February 14 with “Overweight” rating. On Tuesday, August 1 the stock rating was maintained by RBC Capital Markets with “Hold”. The rating was downgraded by Credit Suisse to “Neutral” on Friday, September 8. The stock has “Neutral” rating by Citigroup on Tuesday, April 19.

Investors sentiment decreased to 0.86 in 2017 Q3. Its down 0.08, from 0.94 in 2017Q2. It fall, as 51 investors sold PEP shares while 689 reduced holdings. 106 funds opened positions while 593 raised stakes. 964.87 million shares or 1.00% less from 974.57 million shares in 2017Q2 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0.65% of its portfolio in PepsiCo, Inc. (NASDAQ:PEP). 114,350 are owned by Cypress Asset Tx. Moreover, Fifth Third Fincl Bank has 0.78% invested in PepsiCo, Inc. (NASDAQ:PEP) for 973,570 shares. Reik & Company Limited Liability holds 5,039 shares or 0.19% of its portfolio. Verition Fund Ltd reported 34,110 shares. Bessemer Gp holds 4.26 million shares. Provise Group Ltd Com owns 77,141 shares. 1,681 were reported by Perigon Wealth Mgmt Ltd Liability Corporation. Comml Bank holds 1.3% or 804,747 shares in its portfolio. Salient Tru Lta accumulated 2.16% or 161,611 shares. Seaward Mgmt Partnership holds 1.64% or 300,756 shares. Pettyjohn Wood And White holds 2.47% of its portfolio in PepsiCo, Inc. (NASDAQ:PEP) for 59,866 shares. Swift Run Capital Mgmt invested 0.19% of its portfolio in PepsiCo, Inc. (NASDAQ:PEP). Greenwich Wealth Mgmt Ltd Liability Company holds 2,022 shares or 0.04% of its portfolio. Spinnaker Trust owns 37,476 shares or 0.52% of their US portfolio.

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company has market cap of $2.60 billion. The firm is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It currently has negative earnings. The Company’s biologics product candidates also comprise recombinant human beta -glucuronidase , an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis.

Investors sentiment increased to 1.25 in 2017 Q3. Its up 0.06, from 1.19 in 2017Q2. It is positive, as 17 investors sold Ultragenyx Pharmaceutical Inc. shares while 40 reduced holdings. 15 funds opened positions while 53 raised stakes. 39.75 million shares or 1.85% less from 40.50 million shares in 2017Q2 were reported. Alliancebernstein Lp reported 644,300 shares stake. 2,929 are owned by Sg Americas Ltd Llc. Public Employees Retirement Association Of Colorado owns 6,773 shares or 0% of their US portfolio. Amer International Group has invested 0% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). 2,611 were reported by Tower Research Cap Ltd Co (Trc). Smith Asset Grp L P invested 0.02% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Moreover, Proshare Ltd Liability Com has 0.01% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Adage Capital Prtn Group Lc reported 188,500 shares stake. Oppenheimer Asset Management, a New York-based fund reported 382 shares. Iguana Health Mngmt Ltd Liability Company invested in 50,000 shares. Capital Guardian Trust Company accumulated 521,035 shares. Tiaa Cref Invest Mgmt Lc accumulated 0% or 116,349 shares. Cubist Systematic Strategies Ltd Liability reported 9,287 shares stake. Moreover, Millennium Mngmt Limited Liability Corp has 0.01% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Capital Research Glob holds 0.07% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 4.09 million shares.

Leave a Reply

Your email address will not be published. Required fields are marked *